Toll-like receptor 7

Lupus Research Alliance Honors Carola Vinuesa, MD, PhD, for Discovering a Specific Gene Variant that Causes Lupus in Some Patients

Retrieved on: 
Thursday, June 22, 2023

The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute.

Key Points: 
  • The Lupus Research Alliance awarded its 2023 Lupus Insight Prize to Carola Vinuesa, MD, PhD, of The Francis Crick Institute.
  • Many lupus patients display increased TLR7 activity; however, disease-causing mutations in the TLR7 gene had not been identified.
  • "I am honored to receive this most prestigious award from the Lupus Research Alliance in recognition of our discovery of a genetic cause of lupus.
  • To determine whether the TLR7 mutation identified causes lupus, Dr. Vinuesa's team used a gene-editing tool, CRISPR/Cas9, to introduce the specific variant into mice.

Seven and Eight Biopharmaceuticals Announces Exclusive Clinical License Agreement with Eikon Therapeutics to Develop and Commercialize TLR7/8 dual agonists

Retrieved on: 
Thursday, June 1, 2023

As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).

Key Points: 
  • As part of the agreement, Eikon Therapeutics is awarded global rights to develop and commercialize the company’s novel immune modulator agonists targeting toll-like receptor 7 and 8 (TLR7/8).
  • “We have made great progress in the field of TLR7/8 agonists and advanced our molecules to industry leading positions,” said Walter Lau, Ph.D., Chief Executive Officer of Seven and Eight Biopharmaceuticals.
  • “We are delighted to have the Eikon team continue the clinical development and ultimate commercialization of these molecules.
  • “In addition, encouraging clinical responses have been seen in both mono- and combination therapy in multiple heavily pre-treated tumor types.